Cardiology

A recent analysis from Tulane University has found a healthy sleep pattern could at least partially offset risk of stroke or cardiovascular disease in patients with a high genetic risk.

An assessment of metoprolol in older patients with COPD had to be discontinued after treated patients reported a greater rate of hospitalization due to exacerbations.

The approval makes it the first indicated by the FDA for cardiovascular risk reduction among patients with elevated triglyceride levels, as an add-on to maximally tolerated statin therapy.

The Senate voted 72-18 to support the successor to Scott Gottlieb, MD, following a November hearing which raised questions to his stance on proposed tobacco and e-cigarette policies.

An analysis of the Dongfeng-Tongi cohort has revealed sleeping more than 9 hours per night or taking midday naps lasting longer than 90 minutes was associated with an increase in risk of total stroke.

A new study of more than 60,000 individuals over the course of a decade suggests non-Hispanic blacks were less likely to use and see benefits from low-dose aspirin in the same way as non-Hispanic whites.

An analysis of nearly 7000 health records led to insights into factors of fragmented care for patients with sickle cell disease.

An updated meta-analysis from ASH 2019 is detailing the apparent risk of atrial fibrillation and major bleeding associated with ibrutinib use in patients with hematologic malignancies.

How technology, innovation, and preventive care drove the last 10 years of improved public heart health.

Earlier this year, the American College of Cardiology and the American Heart Association updated treatment guidelines for the primary prevention of cardiovascular disease. They discourage the use of aspirin for this purpose, but in high-risk patients who are not at risk of bleeding, aspirin continues to be part of combination treatment regimens. In this slideshow, we highlight recent findings on aspirin use.

A new study presented at ASH 2019 is providing further evidence for the use of weight-adjusted rivaroxaban in children with venous thromboembolism.